Ikaria Acquisition Diversifies And Strengthens Mallinckrodt’s Hospital Care Portfolio

But, with its $2.3 billion purchase price, Mallinckrodt is betting it can withstand a patent challenge to INOmax, an inhaled nitric oxide drug/device combo product, from an industrial gas company.